Drotaverinum tab 40mg 20 pc

Description

Composition
Active substance:
1 tablet contains: drotaverine hydrochloride in terms of 100% substance – 40 mg ;.
Product form:
Tablets of 40 mg.
Contraindications
hypersensitivity; severe liver and kidney failure; severe chronic heart failure; lactose intolerance, lactase deficiency or glucose-galactose malabsorption; Children up to age 3 years.
Precautions prescribed to patients with arterial hypertension, prostatic hypertrophy, angle-closure glaucoma.
Dosage
40 mg
Indications
Smooth muscle spasm in diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, an inflammation of duodenal papilla.
Smooth muscle spasm of urinary tract diseases: nefrourolitiaz, uretrolitiaz, pyelitis, cystitis, bladder spasm.
As an adjuvant therapy: with smooth muscle spasm of the gastrointestinal tract: gastric ulcer and duodenal ulcer, gastritis, gastric cardia and pyloric spasm, enteritis, colitis, spastic colitis, constipation and irritable bowel syndrome with bloating; tensor headache; dysmenorrhoea, threatening miscarriage, threatening preterm delivery, prolonged disclosure of uterine throat, after-pains.
In carrying out some of the tools of research, including holetsistografii.
Interaction with other drugs
Attenuates levodopa antiparkinsonian effect (increased rigidity and tremor).
It enhances the skin effect of papaverine, bendazol and other antispasmodics, including m-holinoblokatory.
Reduces spazmogennoe morphine activity.
Phenobarbital increases the antispasmodic action Drotaverinum.
Overdose
Overdose symptoms: weakness, decreased blood pressure.
Treatment: symptomatic (blood pressure maintenance).
pharmachologic effect
Pharmacological group:
Antispasmodic.
Pharmacodynamics:
Myotropic antispasmodic, a derivative of isoquinoline. inhibits phosphodiesterase
PDE-4, which leads to the accumulation of intracellular cyclic adenosine monophosphate (cAMP) and as a result in inactivation of myosin light chain kinase, resulting in smooth muscle relaxation.
Regardless of the type of autonomic innervation, Drotaverinum acts on the smooth muscle in the gastrointestinal tract, biliary tract, urinary and cardiovascular systems. In the myocardium and blood vessels enzyme hydrolyzing cAMP is a PDE-3, which explains the lack of serious side effects of the cardiovascular system and unexpressed therapeutic effect against cardiovascular system.
Pharmacokinetics:
Fast and is well absorbed in the gastrointestinal tract. Absorption – 100%. However, 65% of the dose enters the systemic circulation (the “first pass” through the liver). Time to maximum concentration – 45-60 minutes.
Communication with plasma proteins – 95-97%, preferably albumin, gamma and beta globulins, and high density lipoproteins. Evenly distributed in the body, it enters the smooth muscle cells. It does not cross the blood-brain barrier. Drotaverine and / or its metabolites can slightly penetrate the placenta.
Almost completely metabolized in the liver by O-dezetilirovaniya. Metabolites are rapidly conjugated with glucuronic acid. The main metabolite – 4′-dezetildrotaverin, other metabolites – 6 dezetildrotaverin and 4′-dezetildrotaveraldin.
The half -. For 8-10 h 72 h almost completely excreted, over 50% of the kidney (primarily as metabolites) and about 30% of the intestine. Drotaverinum unchanged in the urine is detected.
Pregnancy and breast-feeding
During pregnancy can be applied with caution (on doctor’s advice); The drug is contraindicated during lactation.
Conditions of supply of pharmacies
Without recipe.
side effects
Cardio-vascular system: palpitations, tachycardia, decreased blood pressure.
Central nervous system: dizziness, headache, and insomnia.
On the part of the gastrointestinal tract: nausea, constipation.
Allergic reactions: angioedema, urticaria, rash, itching.
special instructions
In the treatment of gastric ulcer and duodenal ulcer is used in combination with other anti-ulcer agents.
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions, with the appearance of dizziness.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C.
In the reach of children.
Dosing and Administration
Drotaverinum taken orally.
Adults 40-80 mg (1-2 tablets) 3 times a day.
Children aged 3-6 years – 40-120 mg (1-3 tablets) in 2-3 doses, with a maximum daily dose – 120 mg; 6-18 years – 80-200 mg (2-5 tablets) in 2-5 receptions; maximum daily dose – 240 mg.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist